Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking

What Was Tested

This controlled clinical trial paper looks at Therapeutic nicotine (patch, non-peptide).

The purpose of this study was to examine the possible role of nicotine in enhancing coagulation and to assess the potential cardiovascular toxicity of transdermal nicotine therapy for smoking cessation.

Why It Was Studied

A likely contributing mechanism is activation of coagulation.

The role of nicotine in enhancing coagulability has not been resolved.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, men only.

The researchers compared in a crossover study the effects of cigarette smoking, transdermal nicotine and placebo transdermal nicotine, each for 5 days, in 12 healthy smokers.

How the Study Was Run

The design is described as placebo-controlled and crossover.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

The methods mention a period of 5 days.

What Was Measured

Topics PubMed links to this paper include 6-Ketoprostaglandin F1 alpha, Administration, Cutaneous, Blood Coagulation, Cell Adhesion Molecules, Coronary Disease, Eicosanoids and Factor VII.

What This Means in Plain Language

The paper is a placebo-controlled and crossover study of Therapeutic nicotine (patch, non-peptide) over 5 days.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1993 (Journal of the American College of Cardiology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.